AB-101

AB-101 is our oral PD-L1 inhibitor.

The immune system of HBV chronically infected patients is tolerized to recognize the virus or infected cells. To achieve a functional cure and long-term HBV viral control, it is believed that highly functional HBV specific T-cells are required.

Immune checkpoints such as PD-1/PD-L1 play an important role in the induction and maintenance of immune tolerance and in T-cell activation.   

Clinical data to-date

AB-101 has completed a Phase 1a/1b clinical trial evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and multiple-ascending oral doses in healthy subjects and patients with cHBV infection. The data from healthy subjects in Parts 1 and 2 and cHBV patients in Part 3 of this clinical trial have shown that AB-101 was generally well-tolerated with evidence of high receptor occupancy in seven cHBV patients and HBsAg decline in two cHBV patients at the 30mg dose.